Comparative Pharmacology
Head-to-head clinical analysis: SULTEN 10 versus TRIPLE SULFOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULTEN 10 versus TRIPLE SULFOID.
SULTEN-10 vs TRIPLE SULFOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selectively inhibits type 5 phosphodiesterase (PDE5), enhancing cyclic guanosine monophosphate (cGMP) accumulation, leading to smooth muscle relaxation and vasodilation in the corpus cavernosum.
Triple sulfoid (sulfadiazine, sulfamethazine, sulfamerazine) competes with para-aminobenzoic acid (PABA) to inhibit dihydropteroate synthase, blocking bacterial folate synthesis.
1 to 2 tablets (10-20 mg) orally once daily, preferably in the morning.
2 tablets orally every 6 hours for 10-14 days; each tablet contains sulfadiazine 270 mg, sulfamerazine 270 mg, and sulfamethazine 270 mg.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours; clinically, this supports once-daily dosing with steady state achieved in 3-5 days.
10-12 hours in normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min)
Primarily renal excretion of unchanged drug (approx. 70-80%) with the remainder as inactive metabolites (10-15% fecal, 5-10% biliary).
Renal: ~70% as unchanged drug; hepatic metabolism: ~20%; fecal: ~10%
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic